Trump increased investments in drugmakers that benefited from Medicare exemptions, Democrats say

Investments in pharmaceutical companies made on behalf of President Donald Trump surged after he returned to the White House last year, according to a report from congressional Democrats. The report indicated that his pharmaceutical stock holdings grew from $1.7 million in 2024 to up to $56.2 million by the end of 2025. This increase included up to $39.1 million worth of stock in companies that benefited from exemptions to Medicare's drug price negotiation program, which was included in Republicans' 2025 tax and spending law.

The Republican president's wealth has grown since his inauguration through various business interests, many of which have benefited from the administration's policy decisions.

Democrats argue that the exemptions policy could result in Medicare beneficiaries paying significantly more for certain cancer treatments and other medications compared to what they would pay if Medicare could negotiate lower prices. This comes as Trump has emphasized lowering prescription drug costs as a key aspect of his healthcare policy, although the impact of his deals with pharmaceutical companies on affordability remains a subject of debate.

Recent polling suggests that many Americans believe Trump is profiting from his presidency in an unethical or illegal manner, focusing more on his wealth than on helping ordinary citizens. The White House denies any ethical concerns, claiming Democrats are attempting to fabricate conflicts of interest.